Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP3 | P05413 | 1/20 | 0.38 |
| ▸ | FABP4 | P15090 | 1/20 | 0.38 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | MDM4 | O15151 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | TYR | P14679 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.37 |
| ▸ | CA5A | P35218 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Egualen SCHEMBL14482099 | 0.99 | FABP3 (0.37) | FABP3FABP4FABP5KDM4EHDAC4 | |
| Egualen SCHEMBL668397 | 0.99 | FABP3 (0.39) | FABP3FABP4FABP5KDM4EHDAC4 | |
| Egualen SCHEMBL10805301 | 0.97 | FABP3 (0.38) | FABP3FABP4FABP5KDM4EHDAC4 | |
| SCHEMBL10803865 | 0.91 | FABP3 (0.36) | FABP3FABP4FABP5KDM4EHDAC4 | |
| SCHEMBL10804152 | 0.89 | FABP3 (0.36) | FABP3FABP4FABP5KDM4EHDAC4 | |
| SCHEMBL10803313 | 0.88 | ELANE (0.36) | FABP3FABP4FABP5KDM4EHDAC4 | |
| SCHEMBL10803533 | 0.87 | ELANE (0.37) | — | |
| SCHEMBL10810406 | 0.87 | ELANE (0.36) | FABP3FABP4FABP5KDM4EHDAC4 | |
| SCHEMBL7787569 | 0.86 | FABP3 (0.36) | FABP3FABP4FABP5KDM4EHDAC4 | |
| SCHEMBL10810625 | 0.85 | ELANE (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102861337-B | One kind contains solid formulation of egualen sodium | 北京阜康仁生物制药科技有限公司 | 2017-08-11 | — | — | CN | claimed |
| CN-101732290-B | Stable solid formulation of egualen sodium | KOTOBUKI PHARMACEUTICAL CO LTD | 2013-08-28 | — | — | CN | claimed |
| CN-102861337-A | Egualen sodium containing solid preparation | BEIJING FUKANGREN BIOPHARMACEUTICAL TECHNOLOGY CO LTD | 2013-01-09 | — | — | CN | claimed |
| CN-101732290-A | Stable solid formulation of egualen sodium | KOTOBUKI PHARMACEUTICAL CO LTD | 2010-06-16 | — | — | CN | claimed |
| CN-101065121-A | Therapeutic or preventive composition for gastric mucosa disease | KOTOBUKI PHARMACEUTICAL CO LTD (JP) | 2007-10-31 | — | — | CN | claimed |
| EP-0147915-B1 | NEW AZULENE DERIVATIVES USEFUL AS ANTI-ULCERATIVE AND ANTI-FLAMMATORY AGENTS | Kotobuki Seiyaku Co., Ltd. (JP) | 1987-05-06 | — | — | EP | claimed |
| US-4595694-A | Peptic ulcer treatment | KOTOBUKI SEIYAKU CO. LTD. (JP) | 1986-06-17 | — | — | US | claimed |
| EP-0147915-A1 | New azulene derivatives useful as anti-ulcerative and anti-flammatory agents | Kotobuki Seiyaku Co., Ltd. (JP) | 1985-07-10 | — | — | EP | claimed |
| US-12485088-B2 | Rapidly-orodispersible tablets having an interior cavity | Aprecia Pharmaceuticals LLC (US) | 2025-12-02 | — | — | US | disclosed |
| US-12324856-B2 | Oral drug dosage form comprising drug in the form of nanoparticles | Triastek, Inc. (CN) | 2025-06-10 | — | — | US | disclosed |
| EP-4512394-A2 | DOSAGE FORMS AND USE THEREOF | Triastek, Inc. (CN) | 2025-02-26 | — | — | EP | disclosed |
| US-20240408023-A1 | DOSAGE FORMS OF CONTROLLED RELEASE AT SPECIFIC GASTROINTESTINAL SITES | Triastek, Inc. (CN) | 2024-12-12 | — | — | US | disclosed |
| EP-4171518-B1 | RAPIDLY-ORODISPERSIBLE TABLETS HAVING AN INTERIOR CAVITY | Aprecia Pharmaceuticals LLC (US) | 2024-12-11 | — | — | EP | disclosed |
| US-20240342094-A1 | COMPARTMENTED PHARMACEUTICAL DOSAGE FORMS | Triastek, Inc. (CN) | 2024-10-17 | — | — | US | disclosed |
| WO-1996016656-A1 | CONDENSED IMIDAZOLE DERIVATIVES, THEIR PREPARATION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-06-06 | — | — | WO | disclosed |
| US-5312818-A | (Interphenylene)7-oxabicycloheptane substituted (di)amide prostaglandin analog | E. R. SQUIBB & SONS, INC. (US) | 1994-05-17 | — | — | US | disclosed |
| EP-0448274-A2 | Use of a thromboxane A2 receptor antagonist for the manufacture of a medicament for the treatment of ulcerative gastrointestinal conditions | E.R. SQUIBB & SONS, INC. (US) | 1991-09-25 | — | — | EP | disclosed |
| EP-0147915-B1 | NEW AZULENE DERIVATIVES USEFUL AS ANTI-ULCERATIVE AND ANTI-FLAMMATORY AGENTS | Kotobuki Seiyaku Co., Ltd. (JP) | 1987-05-06 | — | — | EP | disclosed |
| US-4595694-A | Peptic ulcer treatment | KOTOBUKI SEIYAKU CO. LTD. (JP) | 1986-06-17 | — | — | US | disclosed |
| EP-0147915-A1 | New azulene derivatives useful as anti-ulcerative and anti-flammatory agents | Kotobuki Seiyaku Co., Ltd. (JP) | 1985-07-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12324856-B2 | Oral drug dosage form comprising drug in the form of nanoparticles | CYP2D6, CYP3A5, CYP3A7 | FABP3 3498/4885FABP4 2900/4885FABP5 3466/4885 |
| US-20240342094-A1 | COMPARTMENTED PHARMACEUTICAL DOSAGE FORMS | CYP2D6, CYP3A5, CYP2F1 | FABP3 3746/4885FABP4 2678/4885FABP5 3250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.